Ganetespib
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Ganetespib, under development by Synta, is a small molecule inhibitor of HSP90. HSP90 is a chaperone protein required to drive growth, proliferation, and cell survival in tumor tissue. Many oncogenic proteins rely on HSP90, and the inhibition of this molecule causes the degradation and death of these proteins.
Analyst Outlook
Ganetespib is a small molecule inhibitor of heat-shock protein 90 (hsp90), under development for acute myeloid leukemia (AML). Early Phase I and Phase II studies indicate that ganetespib has a biological effect in AML, but late-stage data are required to fully evaluate patient outcomes. If approved, ganetespib would compete with Boehringer Ingelheim’s pipeline candidate volasertib. Synta Pharmaceuticals should seek a commercial partner in order to effectively compete with Boehringer Ingelheim’s commercial capabilities.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 ganetespib : Acute myeloid leukemia
LIST OF FIGURES
6 Figure 1: Ganetespib – SWOT analysis for AML
7 Figure 2: Datamonitor Healthcare’s drug assessment summary for ganetespib in AML
8 Figure 3: Datamonitor Healthcare’s drug assessment summary for ganetespib in AML
LIST OF TABLES
4 Table 1: Ganetespib drug profile for acute myeloid leukemia
5 Table 2: Summary of clinical trial development of ganetespib in acute myeloid leukemia
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
ProstAtak 
Sign up to the